Welcome, Guest. Please login or register.
June 25, 2019, 10:12:08 pm

Login with username, password and session length

  • Total Posts: 745585
  • Total Topics: 62329
  • Online Today: 312
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 am)
Users Online
Users: 4
Guests: 247
Total: 251


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Fostemsavir Offers HIV Treatment Hope to Those With No Other Options  (Read 326 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 12,332
  • Twitter @JimAllenDublin
    • HIV Lessons
That's good news.


ViiV Healthcare’s investigational entry inhibitor fostemsavir has helped fully suppress HIV in a majority of those with virus so severely multidrug-resistant that they had only a maximum of two other antiretroviral (ARV) options, aidsmap reports.

Presenting their findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) in Scotland, researchers conducted a study, called BRIGHTE, that included 371 people with multidrug-resistant HIV. Ninety-two of them had no approved ARVs left that would work against their virus and 272 of them had either one or two workable ARVs remaining.

Those in the group that had one or two workable ARVs were randomized to receive fostemsavir (203 people) or a placebo for eight days (69 people), after which they all received fostemsavir on an open-label basis (meaning they knew they were taking the active drug) plus what is known as an optimized background regimen of ARVs.

The participants who had no approved ARVs left that would suppress their virus were all immediately put on fostemsavir and an optimized background regimen, which could include investigational drugs.

On average, participants began the study with a baseline viral load of 40,000. Three quarters of them had a CD4 count below 200, indicating an AIDS diagnosis.

Twenty participants died during the study, including eight members of the group that was randomized and 12 members of the group that received treatment immediately.

During the eight-day placebo-controlled period, those who received fostemsavir saw their viral load drop by 0.8 log10, or about 6.5-fold, compared with a 0.2 log10 drop among those who received the placebo.

After 48 weeks, 62 percent of those in the randomized group had a viral load below 40 and 86 percent had a viral load below 400. Of those in the immediate-treatment group, 48 percent had a viral load below 40 and 55 percent had a viral load below 400.

The randomized group experienced an average rise in CD4 count of 139, while the immediate-treatment group gained an average of 64 CD4s.

The treatment was generally relatively safe. The most common adverse health events were nausea, diarrhea and headache. One third of those in the randomized group and 44 percent of those in the immediate-treatment group had to stop treatment at some point.
HIV 101 - Everything you need to know
HIV 101
Transmission and Risks:
HIV Transmission and Risks
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP


Terms of Membership for these forums

© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.